Drug Name Avodart

In Europe, it was indicated for use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m2, or patients with a BMI greater than 27 kg/m2 with associated risk factors, such as type 2 diabetes or dyslipidaemia. In the UK, it was available beginning in July 2006. As of 2008, the drug was available in 56 countries.
Rimonabant (also known as SR141716; trade names Acomplia, Bethin, Monaslim, Remonabent, Riobant, Slimona, Rimoslim, Zimulti, and Riomont) is an anorectic antiobesity drug. It is an inverse agonist for the cannabinoid receptor CB1. Its main effect is reduction in appetite. Rimonabant was the first selective CB1 receptor blocker to be approved for use anywhere in the world.

 

A recent study has shown that lithium carbonate and sodium valproate, another drug traditionally used to treat the disorder, act in the brain by inhibiting PKC’s activity and help to create other compounds that also inhibit the PKC. Lithium carbonate is of little use for someone suffering from depression.
Antabuse, or disulfiram as it is also known, was the first medicine approved for the treatment of alcohol abuse and alcohol dependence by the U.S. Food and Drug Administration. Antabuse is prescribed to help people who want to quit drinking by causing a negative reaction if the person drinks while they are taking antabuse.